º»Å¼º °íÇ÷¾Ð ȯÀÚ¿¡¼ S-(-)-Amlodipine Nicotinate¿Í RamiprilÀÇ À¯È¿¼º ¹× ¾ÈÁ¤¼ºÀÇ ºñ±³ Æò°¡
The Phase 4 Randomized, Public, Parallel, Comparative, Clinical Trial to Compare Efficacy and Safety of S-(-)-Amlodipine Nicotinate with Ramipril in Hypertensive Patients
´ëÇÑ°íÇ÷¾ÐÇÐȸÁö 2011³â 17±Ç 3È£ p.103 ~ p.113
±è¹Î¼®(Kim Min-Suk) - Àü³²´ëÇб³º´¿ø ½ÉÀå¼¾ÅÍ
Á¤¸íÈ£(Jeong Myung-Ho) - Àü³²´ëÇб³º´¿ø ½ÉÀå¼¾ÅÍ
À̹α¸(Lee Min-Goo) - Àü³²´ëÇб³º´¿ø ½ÉÀå¼¾ÅÍ
½ÉµÎ¼±(Sim Doo-Sun) - Àü³²´ëÇб³º´¿ø ½ÉÀå¼¾ÅÍ
¹Ú±ÙÈ£(Park Keun-Ho) - Àü³²´ëÇб³º´¿ø ½ÉÀå¼¾ÅÍ
À±³²½Ä(Yoon Nam-Sik) - Àü³²´ëÇб³º´¿ø ½ÉÀå¼¾ÅÍ
À±ÇöÁÖ(Yoon Hyun-Ju) - Àü³²´ëÇб³º´¿ø ½ÉÀå¼¾ÅÍ
±è°èÈÆ(Kim Kye-Hun) - Àü³²´ëÇб³º´¿ø ½ÉÀå¼¾ÅÍ
È«¿µÁØ(Hong Young-Joon) - Àü³²´ëÇб³º´¿ø ½ÉÀå¼¾ÅÍ
±èÁÖÇÑ(Kim Ju-Han) - Àü³²´ëÇб³º´¿ø ½ÉÀå¼¾ÅÍ
¾È¿µ±Ù(Ahn Young-Keun) - Àü³²´ëÇб³º´¿ø ½ÉÀå¼¾ÅÍ
Á¶Á¤°ü(Cho Jeong-Gwan) - Àü³²´ëÇб³º´¿ø ½ÉÀå¼¾ÅÍ
¹ÚÁ¾Ãá(Park Jong-Chun) - Àü³²´ëÇб³º´¿ø ½ÉÀå¼¾ÅÍ
°Á¤Ã¤(Kang Jung-Chaee) - Àü³²´ëÇб³º´¿ø ½ÉÀå¼¾ÅÍ
Abstract
Background: The aim of this study was to compare the antihypertensive effect of S-(-)-amlodipine nicotinate with ramipril in patients with essential hypertension.
Methods: Total 138 patients (54.5 ¡¾ 10.5 years, 69 males) were enrolled in this study between 2008 and 2010. Amlodipine 2.5 mg or ramipril 2.5 mg was treated once in a day for 8 weeks. Epidemiologic analysis was performed in intend-to-treat group. Efficacy analysis was performed in the differences of diastolic blood pressure in study groups. Abnormal reactions were divided with severities and drug-relationship.
Results: The change of diastolic blood pressures were more prominent with -12.7 ¡¾ 7.02 mm Hg in amlodipine group, and -9.6 ¡¾ 7.38 mm Hg in ramipril group (p = 0.023). The change of systolic blood pressures was higher in amlodipine group with -18.1 ¡¾ 7.91 mm Hg, and -14.3 ¡¾ 11.96 mm Hg in ramipril group (p = 0.047). Blood pressure normalization rates were 81.3% (48 of 59 patients) in amlodipine group, and 61.4% (35 of 57 patients) in ramipril group (p = 0.017). Abnormal reaction occurred in 5.8% (4 of 68 patients) of amlodipine group and 14.2% (10 of 70 patients) of ramipril group (p = 0.102). The most frequent abnormal reaction was respiratory symptom.
Conclusions: S-Amlodipine-Nicotinate was more effective than ramipril in hypertensive patients without significant abnormal reaction.
Å°¿öµå
Hypertension, Calcium channel blocker, Angiotensin converting enzyme inhibitor
KMID :
0648320110170030103
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
S-Amlodipine-Nicotinate was more effective than ramipril in hypertensive patients without significant abnormal reaction.